Table 2.
Immunosuppressive Therapy Associated with Letermovir Episodes (N=42)
| Immunosuppressive Variable | Primary PPx (N=26)a | Secondary PPx (N=16) |
|---|---|---|
| Immunosuppressive agent (at LET initiation), median no. (range) | 2 (2–4) | 2 (2–3) |
| Steroid, no. (%) | 26 (100) | 16 (100) |
| Prednisone dose in mg, median (range)b | 7.5 (5–625) | 5 (5–1250) |
| Azathioprine, no. (%) | 3 (11.5) | 0 |
| Belatacept, no. (%) | 1 (3.8) | 0 |
| Calcineurin inhibitor, no. (%) | 25 (96.2) | 16 (100) |
| Tacrolimus | 17 (65.4) | 14 (87.5) |
| Cyclosporine | 8 (30.8) | 2 (12.5) |
| Mycophenolate, no. (%) | 7 (26.9) | 4 (25) |
| Sirolimus, no. (%) | 1 (3.8) | 0 |
| Alemtuzumab (≤ 12 months before LET initiation), no. (%) | 3 (11.5) | 2 (12.5) |
| Anti-thymocyte globulin (≤ 6 months before LET initiation), no. (%) | 3 (11.5) | 1 (6.3) |
| High dose steroids (≤ 6 months before LET initiation), no. (%) | 10 (38.4) | 6 (37.5) |
LET: letermovir, PPx: prophylaxis.
a
Represents 26 episodes in 25 patients. One patient received letermovir for primary prophylaxis following both second and third bilateral orthotopic lung transplant surgeries.
b
Reflects maximum daily prednisone dose equivalent within 1 month before letermovir initiation.